Home › NDC Lookup › Ingredients › Lidocaine, Menthol › 71073-0207-10
🩹image loading
(from DailyMed)

Gen7T Plus Lidocaine, Menthol 490 mg; 980 mg Patch, 10 patches — NDC 71073-207-10 (Billing 71073-0207-10)

by Beijing HKKY Medical Tech. Co., Ltd. · 10 PATCH in 1 BOX

This is a package of 10 patches of Gen7T Plus Lidocaine, Menthol 490 mg; 980 mg Patch from Beijing HKKY Medical Tech. Co., Ltd., marketed since Jul 2020 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.

NDC 71073-0207-10
🏷️ FDA NDC (as labeled) 71073-207-10 billing pads the product segment with a zero
This package
Contains10 patches Pack sizes2 compare ↓
Main listing for product 71073-207 · Also comes in: 15 patches 71073-207-35
Rx only On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 71073-207-10
Product NDC 71073-207
11-digit billing NDC 71073020710
RxCUI 2199672
UNII 98PI200987, L7T10EIP3A
SPL Set ID 015be552-0a54-4992-a230-e0535f5348c8
Established class (EPC) Amide Local Anesthetic; Antiarrhythmic
Physiologic effect Local Anesthesia
Chemical class Amides
DEA schedule Non-controlled
Marketing category UNAPPROVED DRUG OTHER
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-07-29
Route TOPICAL
Dosage form PATCH
Substance LIDOCAINE; MENTHOL
Quick answers
  • RxCUI (RxNorm): 2199672
Why two NDCs? The FDA registers this code as 71073-207-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 71073-0207-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Antiarrhythmic class.

Pharmacologic class Antiarrhythmic, Amide Local Anesthetic
Drug family (ATC) Antiarrhythmics, class Ib, Local anesthetics, Anesthetics for topical use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

🧪 What is this product?

Gen7T Plus Lidocaine, Menthol is a topical patch containing lidocaine and menthol. Lidocaine is a local anesthetic typically used to numb or reduce sensation in the area where it is applied. Menthol is commonly included in topical products for its cooling sensation. This product is marketed without an approved FDA application and is classified as an unapproved drug.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 15 patches
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
71073-0207-10 You're viewing this Main listing 10 PATCH in 1 BOX 2020-07-29 — Active
71073-0207-35 71073-207-35 15 PATCH in 1 BOX 2020-07-29 — Active

You're viewing the smallest of 2 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This package contains 10 patches — 10 patch in 1 box.
How does this package differ from NDC 71073-0207-35?
Both are Gen7T Plus Lidocaine, Menthol 490 mg; 980 mg Patch — the drug itself is identical. This page's package is the 10 patches one, while NDC 71073-0207-35 is the 15 patches package.
What NDC number is used to bill for this package of Gen7T Plus Lidocaine, Menthol 490 mg; 980 mg Patch?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Gen7T Plus 490 mg/1; 980 mgthis 71073-0207-10 Beijing 10 patches — — FDA listed —
LM Plus Relief 490 mg/1; 980 mg 71436-3571-05 ARI 15 patches — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Jul 2020
📍
2026
Currently FDA-listed
6 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

We could not link this NDC to a current FDA Structured Product Label. An inactive-ingredient list is therefore not available from this source.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBeijing HKKY Medical Tech. Co., Ltd.
Labeler code71073
First marketedJul 2020
Product typeHuman Prescription Drug
Portfolio3 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧪 Inactive Ingredients 📋 Description ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
⛔ Contraindications 32 words ▾

CONTRAINDICATIONS Gen7T Plus Patch ® is contraindicated in patients with a known hypersensitivity to lidocaine, or any of the topical amide-like local anesthetic preparations or to any other component of the product.

⚠️ Warnings ~2 min read ▾

WARNINGS FOR EXTERNAL USE ONLY 1. Do not use : More than 1 patch on your body at a time or on irritated or swollen skin On wounds, damaged or infected skin On eyes, mouth, genitals, or other mucous membranes With a heating pad 2. Consult physician for children under 12 years of age 3.

Stop and consult your prescriber If condition or pain worsens If you are allergic to any of the ingredients in this product If using concurrently with any other external pain-relieving products If you are pregnant, planning to become pregnant, or breastfeeding If symptoms persist for more than 7 days, or symptoms clear up and occur again within 3 days Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you: Shortness of breath Swelling or numbness of the tongue or throat Severe headache or vomiting Dizziness or faintness Changes in vision or speech Excessive dosage, or short interval between doses, can result in high plasma levels and serious adverse effects.

Patients should be instructed to strictly adhere to the recommended dosage and administration guidelines set forth in this literature and on your prescription label. The management of serious adverse reactions may require the use of resuscitative equipment, oxygen or other resuscitative drugs. General information about the safe and effective use Gen7T Plus Patch ® Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet.

Do not use this product for another indication unless instructed and prescribed by a physician. Do not give this drug to anyone else, even if they have the same condition. This product is intended for use as prescribed by a physician.

How should I store Gen7T Plus Patch ® Store product at room temperature at 68°F to 77°F (20°C to 25°C). Keep away from heat or sunlight. Protect from excessive moisture.

Safely discard product after expiration date posted on the product label. Discard patches away from small children or animals. DO NOT use the product after the expiration date printed on the box.

What are the active ingredients in Gen7T Plus Patch ® ? The patch consists of 3.5% lidocaine and 7% menthol.

🤒 Adverse Reactions 92 words ▾

ADVERSE REACTIONS The most common adverse reactions are application site reactions, including dermatitis, itching or scaling. These tend to be dose-limiting and diminish with time. Serious adverse experiences following the administration of Gen7T Plus Patch ® are similar in nature to those observed in other amide anesthetic-containing agents.

These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption, or may result from hypersensitivity, idiosyncrasy, or a diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature.

🔄 Drug Interactions 60 words ▾

DRUG INTERACTIONS Antiarrhythmic Drugs: Gen7T Plus Patch ® should be used with caution in patients receiving Class 1 antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Gen7T Plus Patch ® is used concurrently with other products containing local anesthetic agents the amount absorbed from all formulations must be considered.

🤰 Pregnancy 40 words ▾

PREGNANCY: The safety of Gen7T Plus Patch ® has not been established during pregnancy. There are no well-controlled studies in pregnant women. Gen7T Plus Patch ® should not be used during pregnancy unless absolutely needed and discussed with a physician.

🧒 Pediatric Use 16 words ▾

PEDIATRIC / GERIATRIC USE Safety and effectiveness in pediatric and geriatric patients have not been established.

🆘 Overdosage 44 words ▾

OVERDOSAGE There have been no reports of over-dosage with Gen7T Plus Patch ® . Signs of overdosage would include vomiting, drowsiness, coma, respiratory depression, and seizures. In the case of an overdosage, discontinue the product immediately, treat the patient symptomatically, and institute supportive measures.

🧬 Clinical Pharmacology 216 words ▾

CLINICAL PHARMACOLOGY Lidocaine is a topical anesthetic and stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Menthol has local anesthetic and counterirritant qualities. It also acts as a weak kappa (ĸ) opioid receptor agonist.

Menthol chemically triggers the cold-‐sensitive TRPM-8 receptors in the skin, which are responsible for the well-‐documented cooling sensation that occurs when applied to the skin. Menthol’s analgesic properties are not fully understood; however, they are mediated through a selective activation of ĸ-opioid receptors. Menthol also blocks voltage-‐sensitive sodium channels, reducing neural activity that may stimulate muscle tissue.

Menthol works by targeting the k-‐opioid receptor on the TRPM8 neuron. The TRPM8 neuron is normally activated at temperatures between (8°-28°C). Menthol causes the neuron to fire at temperatures above normal activation, which triggers the characteristic cooling sensation.

Also because of menthol's specific targeting of the k-‐opioid receptor, it is endowed with analgesic properties. Lidocaine is an amide-‐type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. The penetration of Lidocaine into intact skin after application of patch is sufficient to produce an analgesic effect, but less than the amount necessary to produce a complete sensory block.

🧪 Inactive Ingredients 38 words ▾

INACTIVE INGREDIENTS Polyvinyl alcohol, non-crystallizing sorbitol solution, polyacrylic acid, glycerin, carboxymethylcellulose sodium, colloidal silicon dioxide, titanium dioxide, propylene glycol, tartaric acid, magnesium hydroxide, sodium polyacrylate, purified water. PRESCRIBER INFORMATION Gen7T Plus Patch ® (Lidocaine 3.5% / Menthol 7%)

📋 Description 184 words ▾

DESCRIPTION Gen7T Plus Patch ® is a prescription topical patch containing 15 articulated patches or 10 articulated patches. Lidocaine is present in a 3.5% concentration (w/w). It is chemically designated as 2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide and has an empirical formula of C 14 H 22 N 2 O.

The molecular weight of lidocaine is 234.34 g/mol. Lidocaine has an octanol: water partition ration of 43 at pH 7.4, and has the following structure: ** Lidocaine ** Menthol is present in a 7% concentration (w/w). The chemical name is (1R,2S,5R)‐2‐isopropyl-5-methylcyclohexanol.

The empirical formula for Menthol is C 10 H 20 O with a molecular weight of 156.27 g/mol. Menthol contains colorless, hexangonal crystals, usually needle-like; fused masses or crystalline powder with a pleasant, peppermint-like odor. It has a melting point between 31 O C to 36 O C and has the following structure: ** Menthol ** Gen7T Plus Patch ® uses an adhesive hydrogel technology containing lidocaine 3.5% and menthol 7%, applied to a flexible woven polyester backing and protected by a plastic film.

The protective film is removed prior to application to the skin. Lidocaine Menthol

⚠️ Precautions ~2 min read ▾

PRECAUTIONS Because of the possibility of sedation, patients should be cautioned regarding the operation of heavy machinery or automobiles, and any activities made hazardous by decreased alertness. Hepatic Disease: Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of Lidocaine, because of their inability to metabolize Lidocaine normally. Allergic Reactions: Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to Lidocaine.

However, this product should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain. Non-intact Skin: Application to broken or inflamed skin, although not tested, may result in higher blood concentrations of Lidocaine from increased absorption. Gen7T Plus Patch ® is only recommended for use on intact skin.

Eye Exposure: The contact of this product with the eyes, although not studied, should be avoided based on the findings of severe eye irritations with the use of similar products in animals. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns. External Heat Sources: Placement of external heat sources, such as heating pads or electric blankets, over patches is not recommended as this has not been evaluated and may increase plasma Lidocaine levels.

DRUG INTERACTIONS Antiarrhythmic Drugs: Gen7T Plus Patch ® should be used with caution in patients receiving Class 1 antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Local Anesthetics: When Gen7T Plus Patch ® is used concurrently with other products containing local anesthetic agents the amount absorbed from all formulations must be considered. CARC INOGENESIS , MUTAGENESIS , IMPAIRMENT OF FERTILITY : A minor metabolite, 2,6-xylidine, has been found to be carcinogenic in rats.

The blood concentration of this metabolite is negligible following application of topical lidocaine. The effect of Gen7T Plus Patch ® on fertility has not been studied. PREGNANCY: The safety of Gen7T Plus Patch ® has not been established during pregnancy.

There are no well-controlled studies in pregnant women. Gen7T Plus Patch ® should not be used during pregnancy unless absolutely needed and discussed with a physician. NURSING MOTHERS The effect of Gen7T Plus Patch ® on the nursing infant has not been evaluated.

Caution should be exercised when Gen7T Plus Patch ® is administered to a nursing mother. PEDIATRIC / GERIATRIC USE Safety and effectiveness in pediatric and geriatric patients have not been established. ADVERSE REACTIONS The most common adverse reactions are application site reactions, including dermatitis, itching or scaling.

These tend to be dose-limiting and diminish with time. Serious adverse experiences following the administration of Gen7T Plus Patch ® are similar in nature to those observed in other amide anesthetic-containing agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption, or may result from hypersensitivity, idiosyncrasy, or a diminished tolerance on the part of the patient.

Serious adverse experiences are generally systemic in nature.

🍼 Nursing Mothers 32 words ▾

NURSING MOTHERS The effect of Gen7T Plus Patch ® on the nursing infant has not been evaluated. Caution should be exercised when Gen7T Plus Patch ® is administered to a nursing mother.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 47 words ▾

CARC INOGENESIS , MUTAGENESIS , IMPAIRMENT OF FERTILITY : A minor metabolite, 2,6-xylidine, has been found to be carcinogenic in rats. The blood concentration of this metabolite is negligible following application of topical lidocaine. The effect of Gen7T Plus Patch ® on fertility has not been studied.

📄 Package Label / Principal Display Panel 60 words ▾

PRINCIPAL DISPLAY PANEL PATCH Lidocaine 3.5% + Menthol 7% 15 PATCHES PRINCIPAL DISPLAY PANEL NDC 70645-628-35 GEN 7T PLUS PATCH Lidocaine 3.5% + Menthol 7% 15 PATCHES

PRINCIPAL DISPLAY PANEL GEN 7T PLUS PATCH Dispense by Prescription Lidocaine 3.5% + Menthol 7% 10 PATCHES NDC 70645-628-10 GEN 7T PLUS PATCH Dispense by Prescription Lidocaine 3.5% + Menthol 7% 10 PATCHES

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Lidocaine, Menthol — the ingredient across all brands.

Top reported reactions

Pain3,217
Fatigue3,056
Nausea3,046
Headache2,815
Dyspnoea2,182
Pneumonia2,007
Diarrhoea1,981

Reporter sex

49,319 reports

Serious outcomes

Death4,981
Life-threatening4,202
Disabling1,205
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 5,427 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product Marketed without an FDA application

Listed without an FDA application

This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Beijing HKKY Medical Tech. Co., Ltd.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 15 patches (71073-0207-35). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Beijing HKKY Medical Tech. Co., Ltd. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 71071-0001-01 · Bausch 71073-0302-01 · Beijing →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.